Cinacalcet lowers FGF-23 level together with bone metabolism in hemodialyzed patients with secondary hyperparathyroidism

International Urology and Nephrology

Volumn 44, Issue 5, 2012, Pages 1479-1486

  Hryszko, Tomasz ^a   Brzosko, Szymon ^a   Rydzewska Rosolowska, Alicja ^a   Koc Zorawska, Ewa ^a   Mysliwiec, Michal ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Bone metabolism; Cinacalcet; FGF 23; Hemodialysis; Secondary hyperparathyroidism

Indexed keywords

CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CINACALCET; FIBROBLAST GROWTH FACTOR 23; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; VITAMIN D;

ADULT; ARTICLE; BEDTIME DOSAGE; BLOOD SAMPLING; BONE METABOLISM; CALCIUM BLOOD LEVEL; CELL FUNCTION; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MALE; OSTEOBLAST; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SECONDARY HYPERPARATHYROIDISM; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; BONE AND BONES; CALCIMIMETIC AGENTS; COLLAGEN TYPE I; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; NAPHTHALENES; OSTEOBLASTS; OSTEOCALCIN; PARATHYROID HORMONE; PEPTIDES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84867846441     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-011-0050-7     Document Type: Article

References (30)

1. Nemeth EF, Steffey ME, Hammerland LG, Hung BC, van Wagenen BC, DelMar EG, Balandrin MF (1998) Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 95(7): 4040-4045
2. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350(15):1516-1525. doi: 10.1056/NEJMoa031633350/15/1516[pii]
3. Yano S, Suzuki K, Sumi M, Tokumoto A, Shigeno K, Himeno Y, Sugimoto T (2010) Bone metabolism after cinacalcet administration in patients with secondary hyperparathyroidism. J Bone Miner Metab 28(1):49-54. doi:10.1007/s00774-009-0102-6
4. Shigematsu T, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, Koshikawa S (2009) Long-term cinacalcet HCl treatment improved bone metabolism in Japanese hemodialysis patients with secondary hyperparathyroidism. Am J Nephrol 29(3):230-236. doi:000156717[pii]10. 1159/000156717
5. Lien YH, Silva AL, Whittman D (2005) Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 20(6):1232-1237. doi:gfh829[pii]10.1093/ndt/gfh829
6. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T (2004) Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113(4):561-568. doi:10.1172/JCI19081
7. Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG, Juppner H, Lanske B (2004) Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 23(7):421-432. doi:S0945-053X(04)00115-5[pii]10.1016/ j.matbio.2004.09.007
8. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD (2006) Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17(5):1305-1315. doi:ASN.2005111185[pii]10. 1681/ASN.2005111185
9. Antoniucci DM, Yamashita T, Portale AA (2006) Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 91(8):3144-3149. doi:jc.2006-0021[pii]10.1210/jc.2006-0021
10. Samadfam R, Richard C, Nguyen-Yamamoto L, Bolivar I, Goltzman D (2009) Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology 150(11):4835-4845. doi:en.2009-0472[pii]10.1210/en. 2009-0472
11. Ibrahim S, Rashed L (2009) Serum fibroblast growth factor-23 levels in chronic haemodialysis patients. Int Urol Nephrol 41(1):163-169. doi:10.1007/s11255-008-9466-0
12. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359(6):584-592. doi:359/6/584[pii]10.1056/NEJMoa 0706130
13. Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M, Shlipak MG, Whooley MA, Ix JH (2010) The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the heart and soul study. Ann Intern Med 152(10):640-648. doi:152/10/640[pii]10.1059/ 0003-4819-152-10-201005180-00004
14. Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, de Filippi C, Wolf M (2009) Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119(19):2545-2552. doi:CIRCULATIONAHA.108. 844506[pii]10.1161/CIRCULATIONAHA.108.844506
15. Jean G, Bresson E, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C (2009) Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant 24(3):948-955. doi:gfn571[pii]10.1093/ndt/gfn571
16. Kanbay M, Nicoleta M, Selcoki Y, Ikizek M, Aydin M, Eryonucu B, Duranay M, Akcay A, Armutcu F, Covic A (2010) Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease. Clin J Am Soc Nephrol 5(10):1780-1786. doi:CJN.02560310[pii]10.2215/CJN.02560310
17. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, Konig P, Kraatz G, Mann JF, Muller GA, Kohler H, Riegler P (2007) Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the mild to moderate kidney disease (MMKD) study. J Am Soc Nephrol 18(9):2600-2608. doi:ASN.2006080936[pii]10.1681/ASN. 2006080936
18. Kazama JJ, Sato F, Omori K, Hama H, Yamamoto S, Maruyama H, Narita I, Gejyo F, Yamashita T, Fukumoto S, Fukagawa M (2005) Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 67(3):1120-1125. doi:KID178[pii]10.1111/j. 1523-1755.2005.00178.x
19. Nakanishi S, Kazama JJ, Nii-Kono T, Omori K, Yamashita T, Fukumoto S, Gejyo F, Shigematsu T, Fukagawa M (2005) Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 67(3):1171-1178. doi:KID184[pii]10.1111/j. 1523-1755.2005.00184.x
20. Finch JL, Tokumoto M, Nakamura H, YaoW, ShahnazariM, Lane N, Slatopolsky E (2010) Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. Am J Physiol Renal Physiol 298(6):F1315-F1322.doi:00552.2009[pii]10.1152/ajprenal.00552.2009
21. Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD (2010) Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol 5(1):110-116. doi:CJN.03630509[pii]10.2215/CJN.03630509
22. Koizumi M, Komaba H, Nakanishi S, Fujimori A, Fukagawa M (2011) Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant. doi: gfr384[pii]10.1093/ndt/gfr384
23. Marie PJ (2010) The calcium-sensing receptor in bone cells: a potential therapeutic target in osteoporosis. Bone 46(3):571-576. doi:S8756-3282(09)01785- 2[pii]10.1016/j.bone.2009.07.082
24. Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T (2010) PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 299(4):F882-F889. doi: ajprenal.00360.2010[pii]10.1152/ajprenal. 00360.2010
25. Wesseling-Perry K, Pereira RC, Sahney S, Gales B, Wang HJ, Elashoff R, Juppner H, Salusky IB (2011) Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int 79(1):112-119. doi:ki2010352[pii]10. 1038/ki.2010.352
26. Wetmore JB, Santos PW, Mahnken JD, Krebill R, Menard R, Gutta H, Quarles LD (2011) Elevated FGF23 levels are associated with impaired calcium-mediated suppression of PTH in ESRD. J Clin Endocrinol Metab 96(1):E57-E64. doi:jc.2010-1277[pii]10.1210/jc.2010-1277
27. Wesseling-Perry K, Pereira RC, Wang H, Elashoff RM, Sahney S, Gales B, Juppner H, Salusky IB (2009) Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 94(2):511-517. doi:jc.2008-0326[pii]10.1210/jc.2008-0326
28. Malluche HH, Monier-Faugere MC, Wang G, Fraza OJ, Charytan C, Coburn JW, Coyne DW, Kaplan MR, Baker N, McCary LC, Turner SA, Goodman WG (2008) An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol 69(4):269-278
29. Galitzer H, Ben-Dov IZ, Silver J, Naveh-Many T (2010) Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 77(3):211-218. doi:ki2009464[pii]10.1038/ki. 2009.464
30. Block GA, Zaun D, Smits G, Persky M, Brillhart S, Nieman K, Liu J, St Peter WL (2010) Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int 78(6):578-589. doi:ki2010167[pii]0. 1038/ki.2010.167